Cerenome to Present ReSPECT-LMM Data on November 13
The company will share interim clinical trial results for its CNS cancer treatment at the SNO Annual Meeting in Philadelphia.
Updated on Oct. 27, 2026 in Cancer
Live Poll
Should experimental cancer treatments be fast-tracked for use before full regulatory approval?
Cerenome is set to present interim data from its ReSPECT-LMM clinical trial on November 13, 2026, at the Society for Neuro-Oncology 31st Annual Meeting. The trial evaluates the efficacy of REYOBIQ in treating patients with leptomeningeal metastases.
Why it matters
The study aims to provide a potential treatment path for leptomeningeal metastases, a condition that currently lacks any FDA-approved therapeutics. Results from this trial serve as a foundation for a planned Phase 2 dose randomization study in 2027.
The interim report covers the first 10 patients enrolled in the ReSPECT-LMM trial. REYOBIQ, which consists of rhenium-186 chelated inside a nanoliposome, is currently being tested under an FDA-approved Investigational New Drug application.
The players
Cerenome
A Houston-based company developing novel therapeutics for central nervous system cancers.
Society for Neuro-Oncology
A professional organization for experts involved in the research and treatment of neuro-oncological diseases.
The details
REYOBIQ is administered to patients via an intraventricular catheter for local delivery. The findings will be highlighted in a poster presentation abstract coded as CTNI-40 at the Pennsylvania Convention Center.
Timeline
November 12-15, 2026: Society for Neuro-Oncology 31st Annual Meeting
November 13, 2026, 7:30-9:30 p.m. ET: ReSPECT-LMM interim data poster presentation
November 14, 2026, 7:00-8:15 a.m. ET: Sponsored symposium on CNS cancer
2027: Planned start of Phase 2 dose randomization study
The Big Picture
This study follows the established regulatory process of the FDA IND pathway for oncology therapeutics. The data presented acts as a critical milestone for the company to secure alignment for subsequent late-stage registrational trials.
Patients and healthcare providers are awaiting these results to determine if REYOBIQ may become a viable treatment option for leptomeningeal metastases. The trial represents a potential shift in care for individuals facing this condition where no standard therapy currently exists.
The takeaway
The upcoming SNO presentation marks a pivotal step in assessing whether nanoliposome-based radiation can effectively treat metastatic CNS disease. This development highlights the ongoing effort to introduce targeted local therapies for terminal conditions currently lacking approved interventions.
What happens next
Cerenome plans to initiate an FDA-aligned Phase 2 dose randomization study in 2027.
Further reading
Find more clinical updates in the Cancer section.
More information
Learn more about the company and its research on the Cerenome corporate website.
Source note: This article includes information reported by The Manila times.
Live Poll
Should experimental cancer treatments be fast-tracked for use before full regulatory approval?
